Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial

Morales‐Ortega, Alejandro; Farfán‐Sedano, Ana Isabel; Martín‐López, Juan Víctor San; Escribá‐Bárcena, Almudena; Jaenes‐Barrios, Beatriz; Madroñal-Cerezo, Elena; Llarena-Barroso, Cristina; Mesa‐Plaza, Nieves; Frutos‐Pérez, Begoña; Ruiz‐Giardín, José Manuel; Duarte‐Millán, Miguel Ángel; Piedrabuena‐García, Sara Isabel; Carpintero-García, L.; Canalejo-Castrillero, E.; Mora‐Hernández, Belén; García-Parra, Carlos Javier; Magro‐García, Héctor Agustín; Algaba‐García, Alicia; Hernández-Muniesa, Belén; Nasarre‐López, Berta; Ontañón‐Nasarre, Ana; Domínguez‐García, María Jesús; Gómez‐Santos, Dulce; Prieto-Menchero, Santiago; Tena, Jaime García de; Bermejo, Fernando; García‐Gil, Mario; Gonzalo-Pascua, Sonia; Bello, David

doi:10.1002/jmv.28495

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the first trial was the largest (400 patients) 15,25 , our study had 156 patients, followed by one trial from Spain (110 patients) 17 , and another from the Netherlands (66 patients) 16 . Since the first trial, no other trial, including ours, has been able to show significant benefit of imatinib on mortality in patients hospitalized for COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…A single-center trial from Spain was the first stage of a pick-the-winner trial between bariticinib and imatinib (with the third arm of standard of care). 17 Authors recruited 55 patients to the imatinib arm (at 70 days follow-up, 2 patients died in standard of care, 2 in imatinib and none in the bariticinib arms). Our and the Spanish trial did not have any eligibility criteria regarding supplemental oxygen.…”

Section: Discussionmentioning

confidence: 99%

“…The result remained similar at 90 days follow-up (unadjusted HR for mortality 0.53, 95% CI 0.29-0.94). 25 While the first trial was the largest (400 patients) 15,25 , our study had 156 patients, followed by one trial from Spain (110 patients) 17 , and another from the Netherlands (66 patients) 16 .…”

Section: Discussionmentioning

confidence: 99%

“…15 However, subsequent small trials have been inconclusive. 16,17 Since August 2021, the Solidarity Finland trial, in collaboration with the WHO, has evaluated the benefits and harms of imatinib compared to local standard of care in patients hospitalized for COVID-19. Our study is the first to investigate long-term effects of imatinib treatment on COVID-19 and among the few COVID-19 trials on any drug treatment to include a long-term follow-up on overall quality of life and long COVID (synonymously post COVID-19 condition) symptoms.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

Halme,

Laakkonen,

Rutanen

et al. 2024

Preprint

View full text Add to dashboard Cite

We report the short- and long-term results of the SOLIDARITY Finland on mortality and other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 and 03/2023, we randomised 156 patients in 15 hospitals. In the imatinib group, 7.2% of patients had died at 30 days and 13.3% at 1 year and in the standard of care group 4.1% and 8.3% (adjusted HR at 30 days 1.09, 95% CI 0.23-5.07). In a meta-analysis of randomised trials of imatinib versus standard of care (n=732), allocation to imatinib was associated with a mortality risk ratio of 0.73 (95% CI 0.32-1.63). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in standard of care (RR 0.91, 95% CI 0.78-1.06). Of the 21 potential long COVID symptoms, patients often reported moderate or major bother from fatigue (24%), sleeping problems (19%) and memory difficulties (17%). We found no convincing difference between imatinib and standard of care groups in quality of life or symptom outcomes. The evidence raises serious doubts regarding the benefit of imatinib in reducing mortality, improving recovery and preventing potential long COVID symptoms when given to patients hospitalised for COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

Halme,

Laakkonen,

Rutanen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract

Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”

Wu,

Shi

2023

Angiogenesis

View full text Add to dashboard Cite

Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial

Cited by 5 publications

References 30 publications

Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”

Contact Info

Product

Resources

About